EASL Clinical Practice Guidelines

References

[1]Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17: 107115
Abstract | Full Text | Full Text PDF | PubMed | Scopus (344)

[2]Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N. et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013; 57: 964973
CrossRef | PubMed | Scopus (24)

[3]van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 25842593
CrossRef | PubMed | Scopus (187)

[4]Alsop, D., Younossi, Z., Stepanova, M., and Afdhal, N.H. Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 naive patients treated with ledipasvir and sofosbuvir. Hepatology. 2014; 60: 221A

[5]European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55: 245264
Abstract | Full Text | Full Text PDF | PubMed | Scopus (731)

[6]Antaki, N., Craxi, A., Kamal, S., Moucari, R., Van der Merwe, S., Haffar, S. et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report. Liver Int. 2010; 30: 342355
CrossRef | PubMed | Scopus (82)

[7]Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 12071217
CrossRef | PubMed | Scopus (1016)

[8]Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 24052416
CrossRef | PubMed | Scopus (1387)

[9]Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 11951206
CrossRef | PubMed | Scopus (1456)

[10]Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 24172428
CrossRef | PubMed | Scopus (983)

[11]Lawitz, E., Sulkowski, M.S., Ghalib, R., Rodriguez-Torres, M., Younossi, Z.M., Corregidor, A. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384: 17561765
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)

[12]Doab, A., Treloar, C., and Dore, G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis. 2005; 40: S313S320
CrossRef | PubMed | Scopus (80)

[13]Jensen, D.M., OLeary, J.G., Pockros, P.J., Sherman, K.E., Kwo, P.Y., Mailliard, M.E. et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology. 2014; 60: 219A

[14]Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., Reddy, K.R., Hassanein, T., Jacobson, I. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370: 211221
CrossRef | PubMed | Scopus (185)

[15]Andrews, J., Guyatt, G., Oxman, A.D., Alderson, P., Dahm, P., Falck-Ytter, Y. et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66: 719725
Abstract | Full Text | Full Text PDF | PubMed | Scopus (56)

[16]Chevaliez, S. and Pawlotsky, J.M. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008; 22: 10311048
Abstract | Full Text | Full Text PDF | PubMed | Scopus (24)

[17]Kamili, S., Drobeniuc, J., Araujo, A.C., and Hayden, T.M. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012; 55: S43S48
CrossRef | PubMed | Scopus (28)

[18]Martinot-Peignoux, M., Stern, C., Maylin, S., Ripault, M.P., Boyer, N., Leclere, L. et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010; 51: 11221126
CrossRef | PubMed | Scopus (64)

[19]Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T. et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 139: 15931601
Abstract | Full Text | Full Text PDF | PubMed | Scopus (110)

[20]Castera, L., Sebastiani, G., Le Bail, B., de Ledinghen, V., Couzigou, P., and Alberti, A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010; 52: 191198
Abstract | Full Text | Full Text PDF | PubMed | Scopus (84)

[21]Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343350
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1175)

[22]Chevaliez, S., Bouvier-Alias, M., Brillet, R., and Pawlotsky, J.M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009; 4: e8209
CrossRef | PubMed | Scopus (58)

[23]Huisman, M.T., Snoeys, J., Monbaliu, J., Martens, M.A., Sekar, V.J., and Raoof, A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology. 2010; 52: 461A

[24]European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60: 392420
Abstract | Full Text | Full Text PDF | PubMed | Scopus (119)

[25]Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 18781887
CrossRef | PubMed | Scopus (410)

[26]Mishra, P., Florian, J., Qi, K., Zeng, W., Naeger, L.K., Donaldson, E. et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology. 2014; 147: 11961200
Abstract | Full Text | Full Text PDF | Scopus (1)

[27]Pol, S., Sulkowski, M., Hassanein, T., Gane, E., Liyun, N., Ho, H. et al. Successful retreatment with sofosbuvir of HCV genotype 1-infected patients who failed prior therapy with peginterferon plus ribavirin plus one or two additional direct-acting antiviral agents. J Hepatol. 2014; 60: S23
Abstract | Full Text PDF

[28]Dieterich, D., Bacon, B.R., Flamm, S.L., Kowdley, K.V., Milligan, S., Tsai, N. et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology. 2014; 60: 220A

[29]Jacobson, I.M., Dore, G.J., Foster, G.R., Fried, M.W., Radu, M., Rafalsky, V.V. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; 384: 403413
Abstract | Full Text | Full Text PDF | PubMed | Scopus (48)

[30]Manns, M., Marcellin, P., Poordad, F., de Araujo, E.S., Buti, M., Horsmans, Y. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014; 384: 414426
Abstract | Full Text | Full Text PDF | PubMed | Scopus (44)

[31]Dieterich, D., Rockstroh, J.K., Orkin, C., Gutierrez, F., Klein, M.B., Reynes, J. et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis. 2014; 59: 15791587
CrossRef | PubMed | Scopus (7)

[32]Forns, X., Lawitz, E., Zeuzem, S., Gane, E., Bronowicki, J.P., Andreone, P. et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014; 146: 16691679
Abstract | Full Text | Full Text PDF | PubMed | Scopus (54)

[33]Reddy, K.R., Zeuzem, S., Zoulim, F., Weiland, O., Horban, A., Stanciu, C. et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis. 2015; 15: 2735
Abstract | Full Text | Full Text PDF

[34]Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 18891898
CrossRef | PubMed | Scopus (138)

[35]Afdhal, N., Reddy, K.R., Nelson, D.R., Lawitz, E., Gordon, S.C., Schiff, E. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 14831493
CrossRef | PubMed | Scopus (127)

[36]Kowdley, K.V., Gordon, S.C., Reddy, K.R., Rossaro, L., Bernstein, D.E., Lawitz, E. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 18791888
CrossRef | PubMed | Scopus (88)

[37]Townsend, K.S., Osinusi, A., Nelson, A.K., Kohli, A., Gross, C., Polis, M.A. et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on and off antiretroviral therapy: results from the NIAID ERADICATE trial. Hepatology. 2014; 60: 240A

[38]Bourlire, M., Sulkowski, M.S., Omata, M., Zeuzem, S., Feld, J.J., Lawitz, E. et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014; 60: 239A
Abstract | Full Text | Full Text PDF

[39]Bourlire, M., Bronowicki, J.P., de Ledinghen, V., Hzode, C., Zoulim, F., Mathurin, P. et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology. 2014; 60: 1271A

[40]Feld, J.J., Kowdley, K.V., Coakley, E., Sigal, S., Nelson, D.R., Crawford, D. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 15941603
CrossRef | PubMed | Scopus (90)

[41]Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 19831992
CrossRef | PubMed | Scopus (59)

[42]Wyles, D.L., Sulkowski, M.S., Eron, J.J., Trinh, R., Lalezari, J., Slim, J. et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology. 2014; 60: 1136A
CrossRef | PubMed | Scopus (6)

[43]Zeuzem, S., Jacobson, I.M., Baykal, T., Marinho, R.T., Poordad, F., Bourliere, M. et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 16041614
CrossRef | PubMed | Scopus (67)

[44]Andreone, P., Colombo, M.G., Enejosa, J.V., Koksal, I., Ferenci, P., Maieron, A. et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147: 359365
Abstract | Full Text | Full Text PDF | PubMed | Scopus (20)

[45]Poordad, F., Hezode, C., Trinh, R., Kowdley, K.V., Zeuzem, S., Agarwal, K. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370: 19731982
CrossRef | PubMed | Scopus (91)

[46]Jacobson, I.M., Gordon, S.C., Kowdley, K.V., Yoshida, E.M., Rodriguez-Torres, M., Sulkowski, M.S. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 18671877
CrossRef | PubMed | Scopus (290)

[47]Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370: 19932001
CrossRef | PubMed | Scopus (70)

[48]Esteban, R., Nyberg, L., Lalezari, J., Ni, L., Doehle, B., Kanwar, B. et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol. 2014; 60: S4
Abstract | Full Text PDF | PubMed

[49]Lawitz, E., Poordad, F., Brainard, D.M., Hyland, R.H., An, D., Symonds, W.T. et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology. 2013; 58: 1380A

[50]Lawitz, E., Lalezari, J.P., Hassanein, T., Kowdley, K.V., Poordad, F.F., Sheikh, A.M. et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13: 401408
Abstract | Full Text | Full Text PDF | PubMed | Scopus (89)

[51]Zeuzem, S., Dusheiko, G.M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R.H. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. Gastroenterology. 2014; 370: 19932001

[52]Nelson, D.R., Cooper, J.N., Lalezari, J.P., Lawitz, E., Pockros, P.J., Gitlin, N. et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015; 61: 11271135
CrossRef

[53]Moreno, C., Hezode, C., Marcellin, P., Bourgeois, S., Francque, S., Samuel, D. et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015; (in press)
Abstract | Full Text | Full Text PDF

[54]Kapoor, R., Kohli, A., Sidharthan, S., Sims, Z., Petersen, T.L., Osinusi, A. et al. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014; 60: 321A

[55]Pol, S., Reddy, K.R., Baykal, T., Hezode, C., Hassanein, T., Marcellin, P. et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014; 60: 1129A

[56]Gane, E.J., Hyland, R.H., An, D., Svarovskaia, E.S., Pang, P.S., Symonds, W.T. et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014; 60: 1274A

[57]Chevaliez, S., Bouvier-Alias, M., Brillet, R., and Pawlotsky, J.M. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology. 2007; 46: 2231
CrossRef | PubMed | Scopus (86)

[58]Sarrazin, C., Shiffman, M.L., Hadziyannis, S.J., Lin, A., Colucci, G., Ishida, H. et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol. 2010; 52: 832838
Abstract | Full Text | Full Text PDF | PubMed | Scopus (32)

[59]Vermehren, J., Kau, A., Gartner, B.C., Gobel, R., Zeuzem, S., and Sarrazin, C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol. 2008; 46: 38803891
CrossRef | PubMed | Scopus (53)

[60]Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36: S237S244
CrossRef | PubMed

[61]Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L. Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975982
CrossRef | PubMed | Scopus (4896)

[62]Hadziyannis, S.J., Sette, H. Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346355
CrossRef | PubMed

[63]Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958965
Abstract | Full Text | Full Text PDF | PubMed | Scopus (5023)

[64]Shiffman, M.L., Salvatore, J., Hubbard, S., Price, A., Sterling, R.K., Stravitz, R.T. et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007; 46: 371379
CrossRef | PubMed | Scopus (167)

[65]Soza, A., Everhart, J.E., Ghany, M.G., Doo, E., Heller, T., Promrat, K. et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002; 36: 12731279
CrossRef | PubMed | Scopus (149)

[66]Afdhal, N.H., Dieterich, D.T., Pockros, P.J., Schiff, E.R., Shiffman, M.L., Sulkowski, M.S. et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004; 126: 13021311
Abstract | Full Text | Full Text PDF | PubMed | Scopus (267)

[67]Pockros, P.J., Shiffman, M.L., Schiff, E.R., Sulkowski, M.S., Younossi, Z., Dieterich, D.T. et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004; 40: 14501458
CrossRef | PubMed | Scopus (122)

[68]Sulkowski, M.S., Poordad, F., Manns, M.P., Bronowicki, J.P., Reddy, R.K., Harrison, S.A. et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013; 57: 974984
CrossRef | PubMed | Scopus (38)

[69]Alavian, S.M. and Aalaei-Andabili, S.H. Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2012; 10: 203
Abstract | Full Text | Full Text PDF | PubMed | Scopus (2)

[70]Rodis, J.L. and Kibbe, P. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs. 2010; 33: 368373
CrossRef | PubMed | Scopus (11)

[71]Anand, B.S., Currie, S., Dieperink, E., Bini, E.J., Shen, H., Ho, S.B. et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130: 16071616
Abstract | Full Text | Full Text PDF | PubMed | Scopus (83)

[72]Bruggmann, P., Dampz, M., Gerlach, T., Kravecz, L., and Falcato, L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010; 110: 167171
Abstract | Full Text | Full Text PDF | PubMed | Scopus (19)

[73]Le Lan, C., Guillygomarch, A., Danielou, H., Le Dreau, G., Laine, F., Vedeilhie, C. et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol. 2012; 56: 334340
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[74]Siu, L., Foont, J., and Wands, J.R. Hepatitis C virus and alcohol. Semin Liver Dis. 2009; 29: 188199
CrossRef | PubMed | Scopus (28)

[75]Backmund, M., Meyer, K., and Edlin, B.R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis. 2004; 39: 15401543
CrossRef | PubMed | Scopus (69)

[76]Currie, S.L., Ryan, J.C., Tracy, D., Wright, T.L., George, S., McQuaid, R. et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend. 2008; 93: 148154
Abstract | Full Text | Full Text PDF | PubMed | Scopus (31)

[77]Dalgard, O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis. 2005; 40: S336S338
CrossRef | PubMed | Scopus (63)

[78]Grebely, J., Knight, E., Ngai, T., Genoway, K.A., Raffa, J.D., Storms, M. et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol. 2010; 25: 12811284
CrossRef | PubMed | Scopus (30)

[79]Grebely, J., Pham, S.T., Matthews, G.V., Petoumenos, K., Bull, R.A., Yeung, B. et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012; 55: 10581069
CrossRef | PubMed | Scopus (28)

[80]Barnard, R.J., Howe, J.A., Ogert, R.A., Zeuzem, S., Poordad, F., Gordon, S.C. et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013; 444: 329336
CrossRef | PubMed | Scopus (13)

[81]McPhee, F., Hernandez, D., Yu, F., Ueland, J., Monikowski, A., Carifa, A. et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013; 58: 902911
CrossRef | PubMed | Scopus (24)

[82]Sullivan, J.C., De Meyer, S., Bartels, D.J., Dierynck, I., Zhang, E.Z., Spanks, J. et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013; 57: 221229
CrossRef | PubMed | Scopus (21)

[83]Wang, C., Sun, J.H., OBoyle, D.R. 2nd, Nower, P., Valera, L., Roberts, S. et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013; 57: 20542065
CrossRef | PubMed | Scopus (22)

[84]Lenz, O., Verbinnen, T., Fevery, B., Tambuyzer, L., Vijgen, L., Peeters, M. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015; (in press)
PubMed

[85]Krishnan, P., Tripathi, R., Schnell, G., Reisch, T., Beyer, J., Irvin, M. et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology. 2014; 60: 1134A

[86]Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., Doehle, B., McCarville, J.F., Pang, P.S. et al. Baseline and post-baseline resistance analyses of Phase 2/3 studies of ledipasvir/sofosbuvir  RBV. Hepatology. 2014; 60: 1128A
CrossRef

[87]Wyles, D.L., Pockros, P.J., Yang, J.C., Zhu, Y., Pang, P.S., McHutchison, J.G. et al. Retreatment of patients who failed prior sofosbuvir-based regimens with all-oral fixed-dose combination ledipasvir/sofosbuvir plus ribavirin for 12 weeks. Hepatology. 2014; 60: 317A
CrossRef | Scopus (6)

[88]Afdhal, N., Everson, G., Calleja, J.L., McCaughan, G., Symonds, W.T., Denning, J. et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol. 2014; 60: S28
Abstract | Full Text PDF

[89]Flamm, S.L., Everson, G.T., Charlton, M., Denning, J.M., Arterburn, S., Brandt-Sarif, T. et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology. 2014; 60: 320A

[90]Moon, C., Jung, K.S., Kim, D.Y., Baatarkhuu, O., Park, J.Y., Kim, B.K. et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015; 60: 573581
CrossRef

[91]Morgan, R.L., Baack, B., Smith, B.D., Yartel, A., Pitasi, M., and Falck-Ytter, Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158: 329337
CrossRef | PubMed

[92]Singal, A.K., Freeman, D.H. Jr., and Anand, B.S. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010; 32: 851858
CrossRef | PubMed | Scopus (40)

[93]Garcia-Retortillo, M., Forns, X., Feliu, A., Moitinho, E., Costa, J., Navasa, M. et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680687
CrossRef | PubMed | Scopus (313)

[94]Gane, E. and Pilmore, H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation. 2002; 74: 427437
CrossRef | PubMed

[95]Curry, M.P., Forns, X., Chung, R.T., Terrault, N.A., Brown, R. Jr., Fenkel, J.M. et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015; 148: 100107
Abstract | Full Text | Full Text PDF | PubMed | Scopus (4)

[96]Forman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., and Lucey, M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122: 889896
Abstract | Full Text | Full Text PDF | PubMed

[97]Prieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D. et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999; 29: 250256
CrossRef | PubMed | Scopus (408)

[98]Blasco, A., Forns, X., Carrion, J.A., Garcia-Pagan, J.C., Gilabert, R., Rimola, A. et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006; 43: 492499
CrossRef | PubMed | Scopus (159)

[99]Neumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004; 41: 830836
Abstract | Full Text | Full Text PDF | PubMed | Scopus (228)

[100]Berenguer, M., Palau, A., Aguilera, V., Rayon, J.M., Juan, F.S., and Prieto, M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant. 2008; 8: 679687
CrossRef | PubMed | Scopus (137)

[101]Gambato, M., Lens, S., Navasa, M., and Forns, X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014; 61: S120S131
Abstract | Full Text | Full Text PDF

[102]Charlton, M., Gane, E., Manns, M.P., Brown, R.S. Jr., Curry, M.P., Kwo, P.Y. et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148: 108117
Abstract | Full Text | Full Text PDF | PubMed | Scopus (6)

[103]Forns, X., Charlton, M., Denning, J., McHutchison, J.G., Symonds, W.T., Brainard, D. et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology. 2015; (in press)

[104]Reddy, R.K., Everson, G.T., Flamm, S.L., Denning, J.M., Arterburn, S., Brandt-Sarif, T. et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology. 2014; 60: 200A201A

[105]Mantry, P.S., Kwo, P.Y., Coakley, E., Te, H.S., Vargas, H.E., Brown, R.S. et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/r/ombitasvir plus dasabuvir plus ribavirin. Hepatology. 2014; 60: 298A
Abstract | Full Text | Full Text PDF | Scopus (6)

[106]Brown, R.S., Reddy, K.R.J., OLeary, J.G., Kuo, A., Morelli, G., Stravitz, R.T. et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology. 2014; 60: 1269A

[107]Leroy, V., Dumortier, J., Coilly, A., Sebagh, M., Fougerou-Leurent, C., Radenne, S. et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV recurrence after liver transplantation: the ANRS CO23 CUPILT study. Hepatology. 2014; 60: 207A

[108]Potthoff, A., Berg, T., and Wedemeyer, H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol. 2009; 44: 14871490
CrossRef | PubMed | Scopus (12)

[109]Scott, D.R., Wong, J.K., Spicer, T.S., Dent, H., Mensah, F.K., McDonald, S. et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010; 90: 11651171
CrossRef | PubMed | Scopus (36)

[110]Van Wagner, L.B., Baker, T., Ahya, S.N., Norvell, J.P., Wang, E., and Levitsky, J. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol. 2009; 51: 874880
Abstract | Full Text | Full Text PDF | PubMed | Scopus (17)

[111]Orens, J.B., Estenne, M., Arcasoy, S., Conte, J.V., Corris, P., Egan, J.J. et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25: 745755
Abstract | Full Text | Full Text PDF | PubMed | Scopus (560)

[112]Darke, S., Kaye, S., and Duflou, J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction. 2006; 101: 17711777
CrossRef | PubMed | Scopus (36)

[113]Grebely, J., Raffa, J.D., Lai, C., Kerr, T., Fischer, B., Krajden, M. et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011; 18: 3241
CrossRef | PubMed | Scopus (18)

[114]Hagan, H., Pouget, E.R., Des Jarlais, D.C., and Lelutiu-Weinberger, C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008; 168: 10991109
CrossRef | PubMed | Scopus (60)

[115]Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378: 571583
Abstract | Full Text | Full Text PDF | PubMed | Scopus (247)

[116]Shepard, C.W., Finelli, L., and Alter, M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558567
Abstract | Full Text | Full Text PDF | PubMed | Scopus (1448)

[117]Grebely, J. and Dore, G.J. What is killing people with hepatitis C virus infection?. Semin Liver Dis. 2011; 31: 331339
CrossRef | PubMed | Scopus (40)

[118]Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., and Hickman, M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011; 54: 11371144
Abstract | Full Text | Full Text PDF | PubMed | Scopus (73)

[119]Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J. et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012; 55: 4957
CrossRef | PubMed | Scopus (55)

[120]van Heeswijk, R., Vandevoorde, A., Verboven, P., Boogaerts, G., De Paepe, E., van Solingen-Ristea, R. et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. J Hepatol. 2011; 54: S491
Abstract | Full Text PDF

[121]Luo, X., Trevejo, J., Van Heeswijk, R., and Garg, V. No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers. Global Antivir J. 2011; 7: 116117

[122]Deterding, K., Gruner, N., Buggisch, P., Wiegand, J., Galle, P.R., Spengler, U. et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013; 13: 497506
Abstract | Full Text | Full Text PDF | PubMed | Scopus (16)

[123]Kamal, S.M. Acute hepatitis C: a systematic review. Am J Gastroenterol. 2008; 103: 12831297
CrossRef | PubMed | Scopus (63)

[124]Mondelli, M.U., Cerino, A., and Cividini, A. Acute hepatitis C: diagnosis and management. J Hepatol. 2005; 42: S108S114
Abstract | Full Text | Full Text PDF | PubMed | Scopus (46)

[125]Santantonio, T., Wiegand, J., and Gerlach, J.T. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008; 49: 625633
Abstract | Full Text | Full Text PDF | PubMed | Scopus (72)

[126]Strader, D.B., Wright, T., Thomas, D.L., and Seeff, L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39: 11471171
CrossRef | PubMed | Scopus (1348)

[127]Wiegand, J., Jackel, E., Cornberg, M., Hinrichsen, H., Dietrich, M., Kroeger, J. et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004; 40: 98107
CrossRef | PubMed | Scopus (68)

[128]European ATNAHCICP. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011; 25: 399409

[129]Santantonio, T., Fasano, M., Sagnelli, E., Tundo, P., Babudieri, S., Fabris, P. et al. Acute hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology. 2014; 59: 21012109
CrossRef | Scopus (5)

[130]Mangia, A., Santoro, R., Copetti, M., Massari, M., Piazzolla, V., Spada, E. et al. Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol. 2013; 59: 221228
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)

[131]Fierer, D.S., Dieterich, D.T., Mullen, M.P., Branch, A.D., Uriel, A.J., Carriero, D.C. et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis. 2014; 58: 873879
CrossRef | PubMed | Scopus (11)

[132]Camma, C., Almasio, P., and Craxi, A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci. 1996; 41: 12481255
CrossRef | PubMed | Scopus (80)

[133]Gerlach, J.T., Diepolder, H.M., Zachoval, R., Gruener, N.H., Jung, M.C., Ulsenheimer, A. et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003; 125: 8088
Abstract | Full Text | Full Text PDF | PubMed | Scopus (408)

[134]Micallef, J.M., Kaldor, J.M., and Dore, G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13: 3441
CrossRef | PubMed | Scopus (307)

[135]Poynard, T., Regimbeau, C., Myers, R.P., Thevenot, T., Leroy, V., Mathurin, P. et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2002; 1: CD000369
PubMed

[136]Hofer, H., Watkins-Riedel, T., Janata, O., Penner, E., Holzmann, H., Steindl-Munda, P. et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003; 37: 6064
CrossRef | PubMed | Scopus (159)

[137]Pawlotsky, J.M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 11761192
Abstract | Full Text | Full Text PDF | PubMed | Scopus (62)

[138]Pawlotsky, J.M. Hepatitis C treatment: the data flood goes on: an update from the Liver Meeting 2014. Gastroenterology. 2015; 148: 468479
Abstract | Full Text | Full Text PDF